SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-030201
Filing Date
2024-03-04
Accepted
2024-03-04 06:05:38
Documents
16
Period of Report
2024-02-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247768d1_8k.htm   iXBRL 8-K 31465
2 EXHIBIT 99.1 tm247768d1_ex99-1.htm EX-99.1 14504
6 GRAPHIC tm247768d1_ex99-1img001.jpg GRAPHIC 16873
  Complete submission text file 0001104659-24-030201.txt   249559

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ymab-20240229.xsd EX-101.SCH 3006
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ymab-20240229_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ymab-20240229_pre.xml EX-101.PRE 22353
17 EXTRACTED XBRL INSTANCE DOCUMENT tm247768d1_8k_htm.xml XML 3605
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 24712746
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)